Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Regulus Therapeutics
Biotech
Atai, Eli Lilly, Novartis & more—Chutes & Ladders
Atai announces CEO transition plans. Lilly's Alonzo Weems will retire after 27 years. Novartis China President set to lead all ex-US commercial work.
Max Bayer
,
Gabrielle Masson
May 17, 2024 8:30am
The Time 100: Tech influenced VC firm closes first $100M fund
Oct 26, 2022 11:08am
Sanofi walks away from Regulus' kidney disease therapy
Jul 18, 2022 2:40pm
Regulus again reprioritizes in attempt to turn ship around
Oct 13, 2021 11:18am
Boehringer, Dicerna pen $201M pact to hit NASH with RNAi
Nov 2, 2017 6:30am
Chutes & Ladders—Biogen’s longtime CFO Clancy leaves for Alexion
Jun 16, 2017 8:39am
